The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Intravascular hemolysis and the pathophysiology of sickle cell disease
Open accessAbstract
flow, normoxia to hypoxia, isotonic to hypertonic environment, and acidotic to alkalotic milieu.Multiple components contribute to sickle hemoglobinopathy pathophysiology, including primary components arising from HbS polymerization and secondary components that are downstream effects of the HbS polymer. Understanding how these components' complexity is compounded by genetic and environmental modulation provides insight into the well-known clinical heterogeneity of sickle cell disease (SCD).A cardinal feature of SCD pathogenesis involves inflammation, accompanied by heterocellular leukocyte-platelet-erythrocyte-endothelial adhesive events that trigger vaso-occlusive episodes, acute organ ischemia, and reperfusion injury.Twenty-five years ago, epidemiological studies identified leukocytosis, lower HbF levels, and higher total hemoglobin levels as risk factors associated with increasing incidence of acute painful episodes and acute chest syndrome (ACS) (5).The independent association of high total hemoglobin levels with more pain, ACS events, and osteonecrosis was never mechanistically explained; however, it was implied to be a result of increased blood viscosity (Table 1).Recent epidemiological studies found that lower hemoglobin levels and higher intensity of steady-state hemolytic anemia consistently associate with vasculopathic complications of disease, such as stroke, leg ulcers, PH, priapism, and renal failure.This suggests that certain subphenotypes of SCD relate more to hemolytic anemia severity rather than sickle vaso-occlusion.The reader is referred to recent reviews describing the exceptional strides made in understanding the roles of red cell rigidity (6), inflammation, and cell adhesion in sickle vaso-occlusion (7-9).Here, we review the complementary role of intravascular hemolysis and anemia.Hemolysis is a fundamental feature of sickle cell anemia that contributes to its pathophysiology and phenotypic variability.Decompartmentalized hemoglobin, arginase 1, asymmetric dimethylarginine, and adenine nucleotides are all products of hemolysis that promote vasomotor dysfunction, proliferative vasculopathy, and a multitude of clinical complications of pulmonary and systemic vasculopathy, including pulmonary hypertension, leg ulcers, priapism, chronic kidney disease, and large-artery ischemic stroke.Nitric oxide (NO) is inactivated by cell-free hemoglobin in a dioxygenation reaction that also oxidizes hemoglobin to methemoglobin, a non-oxygen-binding form of hemoglobin that readily loses heme.Circulating hemoglobin and heme represent erythrocytic danger-associated molecular pattern (eDAMP) molecules, which activate the innate immune system and endothelium to an inflammatory, proadhesive state that promotes sickle vaso-occlusion and acute lung injury in murine models of sickle cell disease.Intravascular hemolysis can impair NO bioavailability and cause oxidative stress, altering redox balance and amplifying physiological processes that govern blood flow, hemostasis, inflammation, and angiogenesis.These pathological responses promote regional vasoconstriction and subsequent blood vessel remodeling.Thus, intravascular hemolysis represents an intrinsic mechanism for human vascular disease that manifests clinical complications in sickle cell disease and other chronic hereditary or acquired hemolytic anemias.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“As HbF falls and fewer F-cells are protected from HbS polymer damage, the propensity for vascular occlusion and intravascular hemolysis increases with the release of heme products into the circulation that scavenge nitric oxide causing endothelial damage and vasculopathy.[57][58][59]”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Once released, IL-1β binds to IL-1 receptor (IL-1R) on leukocytes and vascular cells, promoting a cascade of downstream events that lead to activation of neutrophils and platelets and upregulation of E-selectin, P-selectin, VCAM-1, ICAM-1, and chemokines such as IL-8 in endothelial cells, all of which promote vaso-occlusion (14, 17) (Figure 1).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vaso-occlusion contributes to ischemia-reperfusion injury, which, along with release of eDAMPs, promotes the progression of sterile inflammation (Figure 1d) in SCD (14, 17, 18).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies in adults with SCD lend further support to the role of hemolysis by showing a link between the hyperhemolysis phenotype of SCD and stroke risk (17).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Unequal protection by HbF across the gamut of sickle cell disease complications might be partially explained by differences in the pathophysiologic roots of these complications.57,58”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Acute painful episodes and acute chest syndrome are a result of sickle vasoocclusion; HbF has the most noticeable beneficial effect on these subphenotypes.”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Priapism, nephropathy, and sickle vasculopathy are associated with hemolysis.”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Survival in Patients with Primary Pulmonary Hypertension
D’Alonzo, G. E., Barst, R. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Fishman, A. P., Goldring, R. M., Groves, B. Μ., Kernis, J. T., et al. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-5-343 · Cited by 3,488
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 1×
“Mortality Increases risk (19, 39, 42, 47, 49, 64, 188) Protective (189) Protective (190)”
Self-citationCerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694
The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin
Rother, R. P., Bell, L. B., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,565
Self-citationPain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330
Self-citationPulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Self-citationCell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., et al. (2002) · Nature Medicine · doi:10.1038/nm799 · Cited by 1,097
Kato, G. J., Gladwin, M. T., & Steinberg, M. H. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.07.001 · Cited by 876
Self-citationCastro, O. L., Brambilla, D. J., Thorington, B. D., Reindorf, C. A., Scott, R., GILLETTE, P. N., Vera, J., & Levy, P. S. (1994) · Blood · doi:10.1182/blood.v84.2.643.643 · Cited by 805
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1038/nm1202-799 · DOI · Paper page
Cited by
Sorted by citations
Items 701–746 of 746
Asghariastanehei, B., Connes, P., Carin, R., Ducray, M., Martin, M., Poutrel, S., Domenech, C., Joly, P., & Nader, É. (2026) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2026.103007
Wang, Z., Yu, X., Liang, J.-L., Chen, Z., Huang, Y., Zeng, Y.-Q., & Yang, L.-Y. (2026) · BMC Genomic Data · doi:10.1186/s12863-026-01432-8
Heme-induced metabolic stress mediates ferroptosis response in sickle erythroblasts
Xi, C., Takezaki, M., Shi, H., Pace, B. S., & Zhu, X. (2026) · Blood Red Cells & Iron · doi:10.1016/j.brci.2026.100091
Structural basis for hemoglobin scavenging by CD163 reveals mechanism of ligand promiscuity
Zhou, R. X., & Higgins, M. K. (2026) · PLoS Biology · doi:10.1371/journal.pbio.3003788
Velmurugan, S., Gopal, N., Ganesan, K., Ganapathy, P., Kulanthaivel, L., & Subbaraj, G. K. (2026) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2026.106468
Frequência de busca por serviços médicos de emergência em pacientes com doença falciforme no Brasil
Contreras, J. C. Z., Ribeiro, A. P. M. R., Santos, C., Santos, C. B. D. A., Pimenta, R., Tirabochi, R. B., & de Bessa, J. (2026) · Población y Salud en Mesoamérica · doi:10.15517/2tyfhj56
Severe Acute Hypertension Causes Hemolysis With Release of PEP and ACE Inhibitor
Fischer, R., Wysocki, J. A., Hassler, L., & Batlle, D. (2026) · Hypertension · doi:10.1161/hypertensionaha.125.26651
Gwarzo, D. H., Kuliya‐Gwarzo, A., Yusuf, A., Abdullahi, S., Idris, I., Jobbi, Y. D., Abdulsalam, K., Galadanci, A., Borodo, A., Musa, B., et al. (2026) · Nigerian Journal of Clinical Practice · doi:10.4103/njcp.njcp_853_25
More than malaria: Exploring Babesia, Leishmania and Trypanosoma in sickle cell disease
Bhosale, C. R., Morcos, Z. L., Escudero, A., Neupane, R., Kahook, Z., Miranda, G., Deehan, E., Gregg, R. K., & Potter, A. K. (2026) · Current Research in Parasitology and Vector-Borne Diseases · doi:10.1016/j.crpvbd.2026.100396
Aurora, T., Hodges, R., Wardell, J., Barton, M., Lipford, J., Takemoto, C. M., Betensky, M., Desai, P., Jacob, S. A., Rai, P., et al. (2026) · The Lancet Haematology · doi:10.1016/s2352-3026(26)00076-1
The many facets of cardiopulmonary complications in sickle cell disease
d’Humières, T., Jeune, S. L., Luna, G. D., Moulin, T., Boyer, L., Derbel, H., Iles, S., Lellouche, N., Fiore, A., Dérumeaux, G., et al. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.05.007
Pyruvate Kinase Activation in the Management of Thalassemia and Sickle Cell Disease
Musallam, K. M., & Andemariam, B. (2026) · Hemoglobin · doi:10.1080/03630269.2026.2682386
Lights, camera, occlusion! watch sickle cells in real time
Gurkan, U. A. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020303
Rajesh, A. S., Thakur, A. K., Patel, N. K., Hota, P. S., Panda, B. K., Meher, S., & Dash, B. P. (2026) · Journal of Applied Hematology · doi:10.4103/joah.joah_4_26
García, N. D., Mantilla, M., Carrillo, F., Ordoñez, L., & Espino, G. (2026) · Research Square · doi:10.21203/rs.3.rs-9635916/v1
Safety and hematologic impact of high-dose N-acetylcysteine infusion in sickle cell disease
Chen, J., Özpolat, T., Fu, X., Sim, M. M. S., Cate, S. A., Dominguez, M., Osborn, W., Koltun, K., Le, J. M., Ling, M., et al. (2026) · Blood Red Cells & Iron · doi:10.1016/j.brci.2026.100101
A global survey of blood transfusion practices for patients with sickle cell disease
Jacobs, J. W., Al‐Riyami, A. Z., Callum, J., Delaney, M., Daniel, D., White, J., Bocquet, C., Farouk, M., Tayou, C. T., Onyenekwu, C. P., et al. (2026) · Transfusion · doi:10.1111/trf.70331
Mustafa, A. E. M., & Ali, N. M. T. (2026) · Healthcare · doi:10.3390/healthcare14142180
Spirometry Patterns in Adult Sickle Cell Disease: A Retrospective Observational Study
Almusally, R. M., Alghamdi, R., Almubarak, M., Ibrahim, M., Alyousif, H., AlElq, Z., Alwaheed, A., Sultan, O. A., Saeed, A. A., Qutub, H. O., et al. (2026) · Saudi Journal of Medicine and Medical Sciences · doi:10.4103/sjmms.sjmms_490_25
Hamzah, S. K., & Hoidy, W. H. (2026) · Pediatric Blood & Cancer · doi:10.1002/1545-5017.70425
Perspective Chapter: Fetal Hemoglobin Modulators
Walke, V. A. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1017037
Epigenetic strategies for fetal hemoglobin induction in sickle cell disease
de Souza, M. M., Pavan, A. R., Pastre, V. G. D. F., Gini, A. L. R., Silva, R. D. A., Lanaro, C., de Albuquerque, D. M., Costa, F. F., Scarim, C. B., Hodgkinson, J. T., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119186 · Cited by 1
Engole, Y. M., Makulo, J. R. R., Nlandu, Y. M., Nkodila, A. N., Bukabau, J. B., Makanzu, B. M., Mvita, Y., Mavungu, J.-M. M., Kajingulu, F., Mokoli, V. M., et al. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2699576
Antibody-Dependent and Antibody-Independent Hemolysis in Sickle Cell Disease
Glover, R. T., & Maitta, R. W. (2026) · Antibodies · doi:10.3390/antib15040070
Harbich, P. F., Auer, L., Tinhofer, F., Burger, A. L., Eberl, T., Weltler, P., Dobner, S., Geppert, A., Huber, K., & Kaufmann, C. C. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70248
Saeed, H. M. (2026) · International Journal of Health Sciences · doi:10.25259/ijhs_140_2026
Powell-Roach, K. L., Ogu, U. O., Culp, E. V., Gupta, K., Lance, E. I., Cao, X., Leo, M. D., Johnson, D. L., Kakhniashvili, D. G., Cruz‐Almeida, Y., et al. (2026) · Medical Sciences · doi:10.3390/medsci14050517
Assessing the Impact of Intravascular Hemolysis on Erythropoiesis in Sickle Cell Disease
Zhang, H., & An, X. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5376-0_26
Proximal tubulopathy in adult sickle cell disease: association of alpha-1 microglobulin
Engole, Y. M., Nlandu, Y. M., Nkodila, A. N., Makanzu, B. M., Mvita, Y., Ngoy, G. M., Mansoni, B. M., Mvibudulu, R. Z., Lukoki, B., Nyemba, S. M., et al. (2026) · Clinics · doi:10.1016/j.clinsp.2026.101064
Metabolic dysregulation linked to sickling tendency in sickle cell anemia independent of HbF
van der Veen, S., Idrizovic, A., Sanavia, T., Adu, E., Allali, S., Benéitez, D., Bartolucci, P., Biemond, B. J., Boaro, M. P., Bourdelier, E., et al. (2026) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2026.103039
Makis, A. C., Saougou, I., & Vlahos, A. P. (2026) · Thalassemia Reports · doi:10.3390/thalassrep16030022
Endothelin receptor antagonism in sickle cell disease: Is the time now?
Kane, B. J., Derebail, V. K., & Kasztan, M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2026-0168
Vieten, B., Vorwerk, J., Morf, J., Dauth, A., Sondermann, S., Schramm, P., Graf, T., von Bubnoff, N. C. C., Oelschläger, L., & Khandanpour, C. (2026) · Clinical Case Reports · doi:10.1002/ccr3.73501
Al‐Agha, M., AlBadr, F. B., Aleem, A., AlGahtani, F. H., Al-shehri, A., Bashiri, F. A., & Alsultan, A. S. (2026) · British Journal of Haematology · doi:10.1111/bjh.70830
Lucero, M. J., Nozik‐Grayck, E., Hassell, K., Irwin, D. C., Buehler, P. W., & Ferguson, S. K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188170
Impact of renal iron overload on sickle cell nephropathy in a humanized mouse model
Sako, M. O., Kane, B. J., Booze, M., Walker, S., Patel, M., Swamigari, S., Nguyen, H., Hyndman, K. A., Mitchell, T., Bolisetty, S., et al. (2026) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00096.2026
Sickle cell anaemia with and without crises: An observational study of pregnancy outcomes
Auger, N., Mailhot‐Diaferia, É., Côté‐Corriveau, G., Paradis, G., Lewin, A., Ayoub, A., Parrot, A.-M., Park, A., & Potter, B. J. (2026) · British Journal of Haematology · doi:10.1111/bjh.70837
Somaili, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187185
OKONJI, K. S., Daramola, A. O., Folaranmi, O. E., & Alade, O. T. (2026) · World Scientific News · doi:10.65770/fpyd6165
Amoo, K. O., Ologun, B. G., Adebunmi, A. E., & Adebajo, G. O. (2026) · Pediatric Oncall · doi:10.7199/ped.oncall.2027.37
Diamantidis, M. D., Argyrakouli, I., Betsi, E., Roupakia, A., Krestinidi, P., Palassopoulou, M., Zayed, O., Karaloizos, L., & Manafas, A. (2026) · Hematology Reports · doi:10.3390/hematolrep18050075
Multi-omic and Survival Analysis of Acute Chest Syndrome Burden in Sickle Cell DiseasePreprint
Kulshrestha, A., Garrett, M. E., Nouraie, S. M., Machado, R. F., Gordeuk, V. R., Gladwin, M. T., Telen, M. J., Ashley‐Koch, A. E., & (TOPMed), N. T.-O. F. P. M. (2026) · medRxiv · doi:10.64898/2026.10.15.26365641
Self-citationPuravet, A., Bouthors, B., Rieu, B., Montade, Q., Pereira, B., Braïlova, M., Sapin, V., & Bouvier, D. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2026-1538
Beyond Silent Infarction: Linking Brain Injury and Intracranial Arteriopathy in Sickle Cell Disease
Rovira, À. (2026) · Canadian Association of Radiologists Journal · doi:10.1177/08465371261502320
Arlet, J., François, L., Jeune, S. L., Bartolucci, P., Habibi, A., & Joseph, L. (2026) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2026.10.001
Haptoglobin as a multifaceted therapeutic agent targeting hemolysis-induced multi-organ injury
Saeed, S., Wang, J., Ming-Ying, G. A. O., Shad, N. A., Li, N., & Gong, Y. (2026) · Chinese Medical Sciences Journal · doi:10.1016/j.cmsj.2026.09.008
Metadata
- Authors
- Kato, G. J., Steinberg, M. H., & Gladwin, M. T.
- Affiliations
- University of Pittsburgh (US)
- Boston University (US)
- Corresponding author
- Gladwin, Mark T.
- Venue
- Journal of Clinical Investigation
- Published
- 2017-03-01
- Volume
- 127
- Issue
- 3
- Pages
- 750-760
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5330745
- OpenAlex
- W2592339311
- Semantic Scholar
- 0c9beb4e3a557982862ac3ec381a89baab12ceae
- Cited by
- 748
- References
- 193
- Citations by year
- 2026: 90 · 2025: 81 · 2024: 76 · 2023: 65 · 2022: 116 · 2021: 81 · 2020: 87 · 2019: 76 · 2018: 53 · 2017: 21
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Patient-Centered Outcomes Research Institute
- University of Pittsburgh
- Hemophilia Center of Western Pennsylvania
- National Institutes of Health (HL098032)
- National Heart, Lung, and Blood Institute (R01HL087681, R01HL068970, P01HL103455, RC2HL101212, R01HL121386, U01HL107443, T32HL007501, R01HL125886, R01HL098032, T32HL110849)
- National Institute on Minority Health and Health Disparities (R01MD009162)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Health Sciences › Medicine › Hematology › Blood properties and coagulation
- Keywords
- intravascular hemolysis, sickle cell disease, free hemoglobin, nitric oxide, methemoglobin, heme, arginase-1, asymmetric dimethylarginine, adenine nucleotides, pulmonary hypertension, inflammation
- MeSH terms
- Anemia, Sickle Cell, Hemolysis, Humans, Methemoglobin, Nitric Oxide, Vascular Diseases, Vasomotor System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
